Abstract
Duchenne Muscular Dystrophy is a lethal X-linked recessive disorder caused by deficiency of the protein dystrophin. It is the most common muscular dystrophy in children (with an incidence of 1 in 3500 male live births), presenting in early childhood (first onset at 3/4 years) and it is characterized by progressive and profound loss of muscle strength, followed by exhaustion of muscular regenerative capacity, fibrosis, and eventually disruption of the muscle tissue architecture. This condition leads to death into the second second/third decade of the patient life. In the last decade, stem cells have received much attention because of their potential use in cell-based therapies for human diseases. At the beginning, the expression of CD133 antigen was seen only in the haematopoietic system-derived CD34+ stem cells. Few years after, a similar population was also identified in muscle. Since 2004 when CD133+ stem cells were discovered, several works showed the pattern of expression of these cells, their ability to differentiate in vitro into specific lineage such as endothelial and muscular, their capacity to migrate from vessels after transplantation into animal model of muscular dystrophy and to participate to muscular regeneration rather than to replenish satellite cells pool. Moreover, CD133+ isolated from blood- and muscle of DMD patients were treated with lentiviral vectors to skip the mutated region of dystrophin in order to express a shorter dystrophin mRNA transcripts showing the correct coding reading frame. Transplanted into dystrophic animal models, these cells were able to ameliorate their pathological phenotype. This approach of using exon-skipping for the expression of human dystrophin within the DMD CD133+ cells should allow the use of the patient’s own stem cells, thus minimizing the risk of immunological graft rejection. According to these characteristic, blood- and muscle-derived CD133+ were considered feasible for a possible clinical usage in transplantation experiments.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benchaouir R, Meregalli M, Farini A, D’Antona G, Belicchi M, Goyenvalle A, Battistelli M, Bresolin N, Bottinelli R, Garcia L, Torrente Y (2007) Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 1:646–657
Bertoni C (2005) Oligonucleotide-mediated gene editing for neuromuscular disorders. Acta Myol 24(3):194–201
Bertoni C (2008) Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides. Front Biosci 13:517–527
Bhatia R, Munthe HA, Williams AD, Zhang F, Forman SJ, Slovak ML (2000) Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation. Exp Hematol 28:1401–1412
Biggar WD, Harris VA, Eliasoph L, Alman. B (2006) Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16:249–255
Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2:82–91
Cossu G, Sampaolesi M (2007) New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends Mol Med 13:520–526
Emery AE (2002) The muscular dystrophies. Lancet 359:687–695
Gavina M, Belicchi M, Rossi B, Ottoboni L, Colombo F, Meregalli M, Battistelli M, Forzenigo L, Biondetti P, Pisati F, Parolini D, Farini A, Issekutz AC, Bresolin N, Rustichelli F, Constantin G, Torrente Y (2006) VCAM-1 expression on dystrophic muscle vessels has a critical role in the recruitment of human blood-derived CD133+ stem cells after intra-arterial transplantation. Blood 108:2857–2866
Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306:1796–1799
Hyser CL, Mendell JR (1988) Recent advances in Duchenne and Becker muscular dystrophy. Neurol Clin 6:429–453
Lang P, Bader P, Schumm M, Feuchtinger T, Einsele H, Fuhrer M, Weinstock C, Handgretinger R, Kuci S, Martin D, Niethammer D, Greil J (2004) Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol 124:72–79
Limsuwan A, Pienvichit P, Limpijankit T, Khowsathit P, Hongeng S, Pornkul R, Siripornpitak S, Boonbaichaiyapruk S (2010) Transcoronary bone marrow-derived progenitor cells in a child with myocardial infarction: first pediatric experience. Clin Cardiol 33:E7–12
McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD (2006) Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16:583–590
Meregalli M, Farini A, Torrente Y (2008) Combining stem cells and exon skipping strategy to treat muscular dystrophy. Expert Opin Biol Ther 8:1051–1061
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021
Negroni E, Riederer I, Chaouch S, Belicchi M, Razini P, Di Santo J, Torrente Y, Butler-Browne GS, Mouly V (2009) In vivo myogenic potential of human CD133+ muscle-derived stem cells: a quantitative study. Mol Ther 17:1771–1778
O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110
Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T, Gussoni E, Kunkel LM, Huard J (2007) Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 15:867–877
Price FD, Kuroda K, Rudnicki MA (2007) Stem cell based therapies to treat muscular dystrophy. Biochim Biophys Acta 1772:272–283
Riviere C, Danos O, Douar. AM (2006) Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13:1300–1308
Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X, Rafii S (2004) Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103:2055–2061
Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D’Angelica M, Kemeny N, Lyden D, Rafii S (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401
Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, Davies K (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4:1441–1444
Torrente Y, Belicchi M, Sampaolesi M, Pisati F, Meregalli M, D’Antona G, Tonlorenzi R, Porretti L, Gavina M, Mamchaoui K, Pellegrino MA, Furling D, Mouly V, Butler-Browne GS, Bottinelli R, Cossu G, Bresolin N (2004) Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 114:182–195
Torrente Y, Belicchi M, Marchesi C, Dantona G, Cogiamanian F, Pisati F, Gavina M, Giordano R, Tonlorenzi R, Fagiolari G, Lamperti C, Porretti L, Lopa R, Sampaolesi M, Vicentini L, Grimoldi N, Tiberio F, Songa V, Baratta P, Prelle A, Forzenigo L, Guglieri M, Pansarasa O, Rinaldi C, Mouly V, Butler-Browne GS, Comi GP, Biondetti P, Moggio M, Gaini SM, Stocchetti N, Priori A, D’Angelo MG, Turconi A, Bottinelli R, Cossu G, Rebulla P, Bresolin N (2007) Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant 16:563–577
Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman. IL (2000) Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 97:14720–14725
Uchida S, Yokoo S, Yanagi Y, Usui T, Yokota C, Mimura T, Araie M, Yamagami S, Amano S (2005) Sphere formation and expression of neural proteins by human corneal stromal cells in vitro. Invest Ophthalmol Vis Sci 46:1620–1625
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012
Acknowledgments
The Stem Cell Laboratory, Department of Neurological Sciences, Università di Milano, has been supported by the Association Monégasque contre les Myopathies (AMM), Associazione La Nostra Famiglia Fondo DMD Gli Amici di Emanuele, the Associazione Amici del Centro Dino Ferrari, Fondazione Cariplo, Fondazione Telethon, EU’s Framework programme 7 Optistem 223098 and Provincia di Trento Fondo 12-03-5277500-01
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Meregalli, M., Farini, A., Torrente, Y. (2012). Duchenne Muscular Dystrophy: Isolation of CD133-Expressing Myogenic Progenitors from Blood and Muscle of DMD Patients. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells,Volume 3. Stem Cells and Cancer Stem Cells, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2415-0_28
Download citation
DOI: https://doi.org/10.1007/978-94-007-2415-0_28
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2414-3
Online ISBN: 978-94-007-2415-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)